The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond

For almost two decades, pioglitazone has been prescribed primarily to prevent and treat insulin resistance in some type 2 diabetic patients. In this review, we trace the path to discovery of pioglitazone as a thiazolidinedione compound, the glitazone tracks through the regulatory agencies, the trek...

Descripción completa

Detalles Bibliográficos
Autores principales: Devchand, Pallavi R., Liu, Tianyun, Altman, Russ B., FitzGerald, Garret A., Schadt, Eric E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180177/
https://www.ncbi.nlm.nih.gov/pubmed/30337873
http://dx.doi.org/10.3389/fphar.2018.01093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180177/
https://www.ncbi.nlm.nih.gov/pubmed/30337873
http://dx.doi.org/10.3389/fphar.2018.01093

Ejemplares similares